Sabra Health Care REIT, Inc. (SBRA)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Rental Revenue	386.48	381.5	376.27	400.59	396.72	430.58
Other Revenue	308.21	284.18	233.26	96.31	-25.8	158.59
Total Revenue	734.01	702.64	644.62	531.95	388.24	600.82
Revenue Growth (YoY	10.21%	9.00%	21.18%	37.02%	-35.38%	-10.08%
Property Expenses	238.98	227.09	195.25	162.61	141.2	131.55
Selling, General & Administrative	50.68	50.07	47.47	39.57	34.67	32.76
Depreciation & Amortization	172.11	169.62	183.09	187.78	178.99	176.74
Provision for Loan Losses	0.67	0.57	-0.19	-0.14	-3.94	-1.86
Total Operating Expenses	461.09	446.21	426	390.11	358.8	342.9
Operating Income	272.92	256.43	218.62	141.84	29.44	257.92
Interest Expense	-111.7	-114.77	-112.96	-105.47	-98.63	-100.52
Other Non-Operating Income	13.84	0.04	-1.9	-1.1	0.37	2.25
EBT Excluding Unusual Items	175.06	141.69	103.76	35.27	-68.82	159.65
Gain (Loss) on Sale of Investments	-	-	-	-7.67	-10.77	-19.15
Gain (Loss) on Sale of Assets	10.29	2.1	-76.33	-12.01	12.3	2.86
Total Insurance Settlements	1.9	2.2	4.2	-	-	-
Asset Writedown	-4.1	-18.47	-14.33	-94.04	-9.5	-4
Other Unusual Items	0.2	0.2	-1.54	2.09	-34.62	-0.23
Pretax Income	183.35	127.72	15.76	-76.36	-111.41	139.13
Income Tax Expense	1.03	1.01	2	1.24	1.85	0.71
Earnings From Continuing Operations	182.33	126.71	13.76	-77.61	-113.26	138.42
Net Income	182.33	126.71	13.76	-77.61	-113.26	138.42
Net Income to Common	182.33	126.71	13.76	-77.61	-113.26	138.42
Net Income Growth	248.73%	821.14%	-	-	-	100.62%
Basic Shares Outstanding	237	233	231	231	219	206
Diluted Shares Outstanding	240	236	233	231	219	207
Shares Change (YoY)	2.63%	1.40%	0.80%	5.42%	5.70%	10.17%
EPS (Basic)	0.77	0.54	0.06	-0.34	-0.52	0.67
EPS (Diluted)	0.76	0.54	0.06	-0.34	-0.52	0.67
EPS Growth	236.12%	807.61%	-	-	-	81.76%
Dividend Per Share	1.200	1.200	1.200	1.200	1.200	1.350
Dividend Growth	-	-	-	-	-11.11%	-25.00%
Operating Margin	37.18%	36.49%	33.91%	26.66%	7.58%	42.93%
Profit Margin	24.84%	18.03%	2.13%	-14.59%	-29.17%	23.04%
EBITDA	440.16	421.19	395.89	323	221.94	433.8
EBITDA Margin	59.97%	59.94%	61.41%	60.72%	57.17%	72.20%
D&A For Ebitda	167.24	164.76	177.27	181.16	192.5	175.89
EBIT	272.92	256.43	218.62	141.84	29.44	257.92
EBIT Margin	37.18%	36.49%	33.91%	26.66%	7.58%	42.93%
Funds From Operations (FFO)	356.93	321.61	296.5	295.88	253.22	346.53
FFO Per Share	1.49	1.36	1.27	1.28	1.15	1.67
Adjusted Funds From Operations (AFFO)	-	338.19	311.33	333.02	297.14	361.17
AFFO Per Share	-	1.43	1.33	1.43	1.35	1.74
FFO Payout Ratio	79.57%	87.11%	93.57%	93.67%	103.83%	80.31%
Effective Tax Rate	0.56%	0.79%	12.71%	-	-	0.51%
Revenue as Reported	733.04	703.24	647.51	624.81	569.55	598.57

Updated Aug 4, 2025. Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.

SEC Filings: 10-K · 10-Q